Results 141 to 150 of about 121,557 (289)

Archivos finales

Territorios, 2015
Revista Territorios
doaj   +1 more source

[As The Lancet Public Health says: Anyone can drown. No one should]. [PDF]

Aten Primaria
Fernández-Guerrero IM.
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Archivos Finales Desafíos 21

, 2018
Este documento contiene en texto completo el articulo Archivos Finales Desafíos 21 publicado en Desafíos; Vol.
Prada Mayorga, Jaime Andrés
core  

[Regulation of health care financing and delivery: analytic contributions from the perspective of industrial organization and the selection dilemmaRegulação do financiamento e da oferta de serviços de saúde: contribuições analíticas a partir da perspectiva da organização industrial e o dilema da seleção]. [PDF]

Rev Panam Salud Publica
Bascolo E, Houghton N, Debrott Sanchez D, Castillo-Laborde C, Sylvain A.   +4 more
europepmc   +1 more source

A FINAL WORD [PDF]

Evolution, 1974
openaire   +2 more sources

Is 'Final' Really Final?

, 2010
Recently, the Appeal Committee of the Hong Kong Court of Final Appeal raised the question of whether that court had the power to hear an appeal against a decision of the Court of Appeal. The decision in question concerned a judgment of professional misconduct against an accountant by a disciplinary committee under the Professional Accountants Ordinance.
openaire   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Archivos Finales Desafíos 11

, 2018
Este documento contiene en texto completo el articulo Archivos Finales Desafíos 11 publicado en Desafíos; Vol.
Prada Mayorga, Jaime Andrés
core  

Doctor Carlos Juan Finlay de Barres, paradigma en valores éticos profesionales

Correo Científico Médico, 2014
Roxana Finalés Hechavarría, Miguel Ángel Olivé Iglesias   +1 more
doaj